Evidence for a common biological basis of the absorption trait, hallucinogen effects, and positive symptoms: Epistasis between 5-HT2a and COMT polymorphisms
Absorption represents a disposition to experience altered states of consciousness characterized by intensively focused attention. It is correlated with hypnotic susceptibility and includes phenomena ranging from vivid perceptions and imaginations to mystical experiences. Based on the assumption that...
Saved in:
Published in | American journal of medical genetics. Part B, Neuropsychiatric genetics Vol. 137B; no. 1; pp. 29 - 32 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
05.08.2005
|
Subjects | |
Online Access | Get full text |
ISSN | 1552-4841 1552-485X |
DOI | 10.1002/ajmg.b.30197 |
Cover
Abstract | Absorption represents a disposition to experience altered states of consciousness characterized by intensively focused attention. It is correlated with hypnotic susceptibility and includes phenomena ranging from vivid perceptions and imaginations to mystical experiences. Based on the assumption that drug‐induced and naturally occurring mystical experiences share common neural mechanisms, we hypothesized that Absorption is influenced by the T102C polymorphism affecting the 5‐HT2a receptor, which is known to be an important target site of hallucinogens like LSD. Based on the pivotal role ascribed to the prefrontal executive control network for absorbed attention and positive symptoms in schizophrenia, it was further hypothesized that Absorption is associated with the VAL158MET polymorphism of the catechol‐O‐methyltransferase (COMT) gene affecting the dopaminergic neurotransmitter system. The Tellegen Absorption Scale was administered to 336 subjects (95 male, 241 female). Statistical analysis revealed that the group with the T/T genotype of the T102C polymorphism, implying a stronger binding potential of the 5‐HT2a receptor, indeed had significantly higher Absorption scores (F = 10.00, P = 0.002), while no main effect was found for the COMT polymorphism. However, the interaction between T102C and COMT genotypes yielded significance (F = 3.89; P = 0.049), underlining the known functional interaction between the 5‐HT and the dopaminergic system. These findings point to biological foundations of the personality trait of Absorption. © 2005 Wiley‐Liss, Inc. |
---|---|
AbstractList | Absorption represents a disposition to experience altered states of consciousness characterized by intensively focused attention. It is correlated with hypnotic susceptibility and includes phenomena ranging from vivid perceptions and imaginations to mystical experiences. Based on the assumption that drug‐induced and naturally occurring mystical experiences share common neural mechanisms, we hypothesized that Absorption is influenced by the T102C polymorphism affecting the 5‐HT2a receptor, which is known to be an important target site of hallucinogens like LSD. Based on the pivotal role ascribed to the prefrontal executive control network for absorbed attention and positive symptoms in schizophrenia, it was further hypothesized that Absorption is associated with the VAL158MET polymorphism of the catechol‐O‐methyltransferase (COMT) gene affecting the dopaminergic neurotransmitter system. The Tellegen Absorption Scale was administered to 336 subjects (95 male, 241 female). Statistical analysis revealed that the group with the T/T genotype of the T102C polymorphism, implying a stronger binding potential of the 5‐HT2a receptor, indeed had significantly higher Absorption scores (F = 10.00, P = 0.002), while no main effect was found for the COMT polymorphism. However, the interaction between T102C and COMT genotypes yielded significance (F = 3.89; P = 0.049), underlining the known functional interaction between the 5‐HT and the dopaminergic system. These findings point to biological foundations of the personality trait of Absorption. © 2005 Wiley‐Liss, Inc. Absorption represents a disposition to experience altered states of consciousness characterized by intensively focused attention. It is correlated with hypnotic susceptibility and includes phenomena ranging from vivid perceptions and imaginations to mystical experiences. Based on the assumption that drug-induced and naturally occurring mystical experiences share common neural mechanisms, we hypothesized that Absorption is influenced by the T102C polymorphism affecting the 5-HT2a receptor, which is known to be an important target site of hallucinogens like LSD. Based on the pivotal role ascribed to the prefrontal executive control network for absorbed attention and positive symptoms in schizophrenia, it was further hypothesized that Absorption is associated with the VAL158MET polymorphism of the catechol-O-methyltransferase (COMT) gene affecting the dopaminergic neurotransmitter system. The Tellegen Absorption Scale was administered to 336 subjects (95 male, 241 female). Statistical analysis revealed that the group with the T/T genotype of the T102C polymorphism, implying a stronger binding potential of the 5-HT2a receptor, indeed had significantly higher Absorption scores (F = 10.00, P = 0.002), while no main effect was found for the COMT polymorphism. However, the interaction between T102C and COMT genotypes yielded significance (F = 3.89; P = 0.049), underlining the known functional interaction between the 5-HT and the dopaminergic system. These findings point to biological foundations of the personality trait of Absorption. Absorption represents a disposition to experience altered states of consciousness characterized by intensively focused attention. It is correlated with hypnotic susceptibility and includes phenomena ranging from vivid perceptions and imaginations to mystical experiences. Based on the assumption that drug-induced and naturally occurring mystical experiences share common neural mechanisms, we hypothesized that Absorption is influenced by the T102C polymorphism affecting the 5-HT2a receptor, which is known to be an important target site of hallucinogens like LSD. Based on the pivotal role ascribed to the prefrontal executive control network for absorbed attention and positive symptoms in schizophrenia, it was further hypothesized that Absorption is associated with the VAL158MET polymorphism of the catechol-O-methyltransferase (COMT) gene affecting the dopaminergic neurotransmitter system. The Tellegen Absorption Scale was administered to 336 subjects (95 male, 241 female). Statistical analysis revealed that the group with the T/T genotype of the T102C polymorphism, implying a stronger binding potential of the 5-HT2a receptor, indeed had significantly higher Absorption scores (F = 10.00, P = 0.002), while no main effect was found for the COMT polymorphism. However, the interaction between T102C and COMT genotypes yielded significance (F = 3.89; P = 0.049), underlining the known functional interaction between the 5-HT and the dopaminergic system. These findings point to biological foundations of the personality trait of Absorption.Absorption represents a disposition to experience altered states of consciousness characterized by intensively focused attention. It is correlated with hypnotic susceptibility and includes phenomena ranging from vivid perceptions and imaginations to mystical experiences. Based on the assumption that drug-induced and naturally occurring mystical experiences share common neural mechanisms, we hypothesized that Absorption is influenced by the T102C polymorphism affecting the 5-HT2a receptor, which is known to be an important target site of hallucinogens like LSD. Based on the pivotal role ascribed to the prefrontal executive control network for absorbed attention and positive symptoms in schizophrenia, it was further hypothesized that Absorption is associated with the VAL158MET polymorphism of the catechol-O-methyltransferase (COMT) gene affecting the dopaminergic neurotransmitter system. The Tellegen Absorption Scale was administered to 336 subjects (95 male, 241 female). Statistical analysis revealed that the group with the T/T genotype of the T102C polymorphism, implying a stronger binding potential of the 5-HT2a receptor, indeed had significantly higher Absorption scores (F = 10.00, P = 0.002), while no main effect was found for the COMT polymorphism. However, the interaction between T102C and COMT genotypes yielded significance (F = 3.89; P = 0.049), underlining the known functional interaction between the 5-HT and the dopaminergic system. These findings point to biological foundations of the personality trait of Absorption. |
Author | Vaitl, Dieter Hennig, Juergen Reuter, Martin Ott, Ulrich |
Author_xml | – sequence: 1 givenname: Ulrich surname: Ott fullname: Ott, Ulrich email: Ulrich.Ott@psychol.uni-giessen.de organization: Center for Psychobiology and Behavioral Medicine, University of Giessen, Germany – sequence: 2 givenname: Martin surname: Reuter fullname: Reuter, Martin organization: Center for Psychobiology and Behavioral Medicine, University of Giessen, Germany – sequence: 3 givenname: Juergen surname: Hennig fullname: Hennig, Juergen organization: Center for Psychobiology and Behavioral Medicine, University of Giessen, Germany – sequence: 4 givenname: Dieter surname: Vaitl fullname: Vaitl, Dieter organization: Center for Psychobiology and Behavioral Medicine, University of Giessen, Germany |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/15965969$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1uEzEUhS1URH9gxxp5xSpT7JnMeIZdlYYU6J9EEN1Ztuc6cbHHw9hpybvwsDhJWyQkkCxdL77vXumcQ7TX-Q4Qek3JMSUkfydu3eJYHheENuwZOqBlmWfjurzZe_qP6T46DOGWkIKUjL1A-7RsqvSaA_Rremda6BRg7QcssPLO-Q5L461fGCUsliKYgL3GcQlYyOCHPpqExEGYOMJLYe1Kmc4voMOgNagYRlh0Le59MNHcAQ5r10fvwns87U2I230S4j0ko8zO5rnY8pOri3mS7NqlE0sTXHiJnmthA7x6mEfo64fpfHKWnV_NPk5OzjM1JjnLmpqyCvKWQltTqhQTdcOIZoQAk0VLWskUrZu2KElFSdXkkqhcV0xqUmsiVHGE3u729oP_sYIQuTNBgbWiA78KvKoJSyZN4JsHcCUdtLwfjBPDmj_mmYDRDlCDD2EA_QchfFMX39TFJd_WlfD8L1yZKDbxbtK1_5KKnXRvLKz_e4CffLqYPVrZzkoNwM8nSwzfecUKVvJvlzNefvl8c3o9u-aXxW8Z3Lrq |
CitedBy_id | crossref_primary_10_1556_2054_2022_00195 crossref_primary_10_17744_mehc_42_4_03 crossref_primary_10_1016_j_pnpbp_2009_04_010 crossref_primary_10_1016_j_neuron_2022_12_031 crossref_primary_10_1177_070674371105600304 crossref_primary_10_1016_j_neubiorev_2018_02_004 crossref_primary_10_1017_S1461145707007900 crossref_primary_10_1017_S0033291723001514 crossref_primary_10_1080_00029157_2021_1943299 crossref_primary_10_1080_00207144_2014_931177 crossref_primary_10_1097_YPG_0b013e32833a212f crossref_primary_10_1080_00223891_2011_627966 crossref_primary_10_1016_j_bandc_2014_10_008 crossref_primary_10_1017_S0033291715002901 crossref_primary_10_3389_fphar_2018_00897 crossref_primary_10_1055_a_1721_2914 crossref_primary_10_1080_08870446_2017_1357814 crossref_primary_10_1093_pnasnexus_pgae066 crossref_primary_10_1093_sleep_32_12_1629 crossref_primary_10_1098_rspb_2007_0876 crossref_primary_10_1016_j_concog_2019_05_008 crossref_primary_10_1016_j_concog_2017_07_009 crossref_primary_10_1080_15287390801985687 crossref_primary_10_4103_psychiatry_IndianJPsychiatry_129_18 crossref_primary_10_1017_S0033291723003653 crossref_primary_10_1093_nc_niae038 crossref_primary_10_1016_j_nsa_2024_104092 crossref_primary_10_4000_12xrc crossref_primary_10_1177_1745691619895047 crossref_primary_10_1016_j_bbr_2010_07_003 crossref_primary_10_3389_fnhum_2014_00771 crossref_primary_10_1371_journal_pone_0030800 crossref_primary_10_1016_j_jad_2024_02_089 crossref_primary_10_1016_j_biopsycho_2012_09_007 crossref_primary_10_1371_journal_pone_0211023 crossref_primary_10_1177_0269881120981384 crossref_primary_10_1007_s11469_024_01253_9 crossref_primary_10_1016_j_bbr_2011_08_012 crossref_primary_10_3389_fpsyg_2018_01424 crossref_primary_10_1021_acsptsci_1c00014 crossref_primary_10_1016_j_bandc_2012_06_001 crossref_primary_10_1016_j_cobeha_2016_10_008 crossref_primary_10_1038_tpj_2011_10 crossref_primary_10_1080_00029157_2020_1865869 crossref_primary_10_1093_nc_niaa004 crossref_primary_10_1177_0269881117725915 crossref_primary_10_1016_j_neulet_2006_07_030 crossref_primary_10_1177_0269881120959637 crossref_primary_10_1080_13674676_2011_637913 crossref_primary_10_2174_1745017900905010009 crossref_primary_10_1007_s00213_014_3714_z crossref_primary_10_1002_hbm_22688 crossref_primary_10_1016_j_paid_2016_02_078 crossref_primary_10_1016_j_ynirp_2023_100171 crossref_primary_10_1038_sj_mp_4001814 crossref_primary_10_1038_s41598_021_01209_2 |
Cites_doi | 10.1097/00041444-200010040-00006 10.1016/S0361-9230(01)00646-3 10.1037/0022-3514.72.4.929 10.1016/S0893-133X(01)00333-5 10.1001/archpsyc.59.1.85 10.1001/archpsyc.60.9.889 10.1073/pnas.0732088100 10.1097/00001756-199812010-00024 10.1016/j.pharmthera.2003.11.002 10.1002/1096-8628(20001204)96:6<831::AID-AJMG27>3.0.CO;2-K 10.1016/S0140-6736(96)90939-3 10.1002/jnr.10173 10.1186/1471-2202-3-14 10.1176/ajp.156.9.1456 10.1111/1467-6494.05018 10.1162/089892902760191117 10.1037/h0036681 10.1002/1096-8628(20001204)96:6<771::AID-AJMG14>3.0.CO;2-T 10.1016/S1053-8100(02)00046-6 10.1097/00008571-199606000-00007 10.1080/00207149408409352 10.1016/S0920-9964(03)00183-X 10.1176/appi.ajp.160.11.1965 10.2466/PR0.83.6.387-391 10.1097/00008571-199702000-00009 10.1080/02791072.2002.10399962 10.1038/sj.npp.1395318 |
ContentType | Journal Article |
Copyright | Copyright © 2005 Wiley‐Liss, Inc. (c) 2005 Wiley-Liss, Inc. |
Copyright_xml | – notice: Copyright © 2005 Wiley‐Liss, Inc. – notice: (c) 2005 Wiley-Liss, Inc. |
DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1002/ajmg.b.30197 |
DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1552-485X |
EndPage | 32 |
ExternalDocumentID | 15965969 10_1002_ajmg_b_30197 AJMG30197 ark_67375_WNG_5SKXDPGP_N |
Genre | shortCommunication Journal Article |
GroupedDBID | .55 .GA .Y3 05W 0R~ 10A 1L6 1OC 23M 31~ 33P 4.4 51W 51X 52N 52O 52P 52S 52T 52W 52X 53G 5GY 5VS 7PT 8-1 8-4 8-5 8UM AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABIJN ABIVO ABJNI ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFO ACGFS ACPOU ACPRK ACXBN ACXQS ADEOM ADIZJ ADKYN ADMGS ADOZA ADZMN ADZOD AEEZP AEIGN AEIMD AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFZJQ AHBTC AIAGR AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN BDRZF BFHJK BRXPI BSCLL BY8 CS3 D-F DCZOG DPXWK DR2 DRFUL DRSTM EBS EJD F00 F01 F04 F5P FEDTE G-S GNP GODZA HBH HGLYW HHY HHZ HVGLF IX1 KQQ LATKE LAW LEEKS LH4 LOXES LP6 LP7 LUTES LYRES MEWTI MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM OIG P2P P2W P4D QB0 QRW ROL RWI SUPJJ UB1 V2E W99 WIH WJL WQJ WRC WXSBR X7M XG1 XV2 AAHQN AAMNL AANHP AAYCA ACRPL ACYXJ ADNMO AFWVQ ALVPJ AAYXX AEYWJ AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c4027-98176e2d1ed811cc7a8970f700e7b3d0db7c189d350610692b0c2f67bf08f0ac3 |
IEDL.DBID | DR2 |
ISSN | 1552-4841 |
IngestDate | Fri Jul 11 01:40:01 EDT 2025 Fri Jun 20 17:44:13 EDT 2025 Thu Apr 24 22:59:17 EDT 2025 Tue Jul 01 04:31:20 EDT 2025 Wed Jan 22 16:45:36 EST 2025 Wed Oct 30 09:47:46 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | http://doi.wiley.com/10.1002/tdm_license_1.1 (c) 2005 Wiley-Liss, Inc. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4027-98176e2d1ed811cc7a8970f700e7b3d0db7c189d350610692b0c2f67bf08f0ac3 |
Notes | ArticleID:AJMG30197 ark:/67375/WNG-5SKXDPGP-N istex:A1E72E12AC58789A8B6009B1788EE5F4B489FA35 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 15965969 |
PQID | 68076101 |
PQPubID | 23479 |
PageCount | 4 |
ParticipantIDs | proquest_miscellaneous_68076101 pubmed_primary_15965969 crossref_primary_10_1002_ajmg_b_30197 crossref_citationtrail_10_1002_ajmg_b_30197 wiley_primary_10_1002_ajmg_b_30197_AJMG30197 istex_primary_ark_67375_WNG_5SKXDPGP_N |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 5 August 2005 |
PublicationDateYYYYMMDD | 2005-08-05 |
PublicationDate_xml | – month: 08 year: 2005 text: 5 August 2005 day: 05 |
PublicationDecade | 2000 |
PublicationPlace | Hoboken |
PublicationPlace_xml | – name: Hoboken – name: United States |
PublicationTitle | American journal of medical genetics. Part B, Neuropsychiatric genetics |
PublicationTitleAlternate | Am. J. Med. Genet |
PublicationYear | 2005 |
Publisher | Wiley Subscription Services, Inc., A Wiley Company |
Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company |
References | Crawford HJ. 1994. Brain dynamics and hypnosis-attentional and disattentional processes. Int J Clin Exp Hypn 42: 204-232. Turecki G, Brière R, Dewar K, Antonetti T, Lesage AD, Séguin M, Chawky N, Vanier C, Alda M, Joober R, Benkelfat C, Rouleau GA. 1999. Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am J Psychiatry 156: 1456-1458. Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Baebler A, Vogel H, Hell D. 1998. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 9: 3897-3902. Tellegen A. 1982. Brief manual for the multidimensional personality questionnaire. Unpublished manuscript. Minneapolis: University of Minnesota. Tellegen A, Atkinson G. 1974. Openness to absorbing and self-altering experiences ("absorption"), a trait related to hypnotic susceptibility. J Abnorm Psychol 83: 268-277. Syvänen AC, Tilgmann C, Rinne J, Ulmanen I. 1997. Genetic polymorphism of catechol-O-methyltransferase (COMT): Correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics 7: 65-71. Nichols DE. 2004. Hallucinogens. Pharmacol Ther 101: 131-181. Donnelly JP. 1998. A continuum model of personality disorder. Psychol Rep: 83: 387-391. Goodman N. 2002. The serotonergic system and mysticism: Could LSD and the nondrug-induced mystical experience share common neural mechanisms? J Psychoactive Drugs 34: 263-272. Borg J, Andrée B, Soderstrom H, Farde L. 2003. The serotonin system and spiritual experiences. Am J Psychiatry 160: 1965-1969. Dietrich A. 2003. Functional neuroanatomy of altered states of consciousness: The transient hypofrontality hypothesis. Conscious Cogn 12: 231-256. Lichtenberg P, Bachner-Melman R, Gritsenko I, Ebstein RP. 2000. Exploratory association study between catechol-O-methyltransferase (COMT) high/low enzyme activity polymorphism and hypnotizability. Am J Med Genet (Neuropsychiatr Genet) 96: 771-774. Polesskaya OO, Sokolov BP. 2002. Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 67: 812-822. Ando J, Ono Y, Yoshimura K, Onoda N, Shinohara M, Kanba S, Asai M. 2002. The genetic structure of Cloninger's seven-factor model of temperament and character in a Japanese sample. J Pers 70: 583-609. Finkel D, McGue M. 1997. Sex differences and nonadditivity in heritability of the Multidimensional Personality Questionnaire Scales. J Pers Soc Psychol 72(4): 929-938. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. 1996. Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6: 243-250. Williams J, Spurlock G, McGuffin P, Mallet J, Nothen MM, Gill M, Aschauer H, Nylander PO, Macciardi F, Owen MJ. 1996. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group. Lancet 347: 1294-1296. Fan J, Fossella J, Sommer T, Wu Y, Posner MI. 2003. Mapping the genetic variation of executive attention onto brain activity. Proc Natl Acad Sci USA 100: 7406-7411. Cloninger CR, Przybeck TR, Svrakic DM, Wetzel RD. 1994. The temperament and character inventory: A guide to its development and use. St Louis: Washington University Center for Psychobiology of Personality. Comings DE, Gonzales N, Saucier G, Johnson JP, MacMurray JP. 2000. The DRD4 gene and the spiritual transcendence scale of the character temperament index. Psychiatr Genet 10: 185-189. Ritz T, Dahme B. 1995. Die Absorption-Skala: Konzeptuelle Aspekte, psychometrische Kennwerte und Dimensionalität einer deutschsprachigen Adaptation [The Absorption Scale: Conceptual aspects, psychometric properties, and dimensionality of a German adaptation]. Diagnostica 41: 53-61. Aghajanian GK, Marek GJ. 1999. Serotonin and hallucinogens. Neuropsychopharmacology 21: 16S-23S. Porras G, Di Matteo V, Fracasso C, Lucas G, De Deurwaerdere P, Caccia S, Esposito E, Spampinato U. 2002. 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 26: 311-324. Raz A, Shapiro T. 2002. Hypnosis and neuroscience: A cross talk between clinical and cognitive research. Arch Gen Psychiatry 59: 85-90. Rainville P, Hofbauer RK, Bushnell MC, Duncan FH, Price DD. 2002. Hypnosis modulates activity in brain structures involved in the regulation of consciousness. J Cogn Neurosci 14: 887-901. Vollenweider FX, Geyer MA. 2001. A systems model of altered consciousness: Integrating natural and drug-induced psychosis. Brain Res Bull 56: 495-507. Bondy B, Kuznik J, Baghai T, Schule C, Zwanzger P, Minov C, de Jonge S, Rupprecht R, Meyer H, Engel RR, Eisenmenger W, Ackenheil M. 2000. Lack of association of serotonin-2A receptor gene polymorphism (T102C) with suicidal ideation and suicide. Am J Med Genet 96: 831-835. Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT. 2004. Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr Res 67: 53-62. Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS, Goldman D, Weinberger DR. 2003. Executive subprocesses in working memory: Relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 60: 889-896. Fossella J, Sommer T, Fan J, Wu Y, Swanson JM, Pfaff DW, Posner MI. 2002. Assessing the molecular genetics of attention networks. BMC Neuroscience 3: 14. 2004; 101 2002; 14 2002; 59 2002; 34 2004; 67 2002; 3 1999; 21 1994 1998; 83 1997; 7 1994; 42 2003; 12 1996; 347 1995; 41 2002; 26 1997; 72 1974; 83 2000; 10 2002; 67 2000; 96 2003; 160 2002; 70 1982 1999; 156 2003; 60 2001; 56 2003; 100 1996; 6 1998; 9 Cloninger (10.1002/ajmg.b.30197-BIB6) 1994 Nichols (10.1002/ajmg.b.30197-BIB18) 2004; 101 Vollenweider (10.1002/ajmg.b.30197-BIB29) 1998; 9 Bondy (10.1002/ajmg.b.30197-BIB4) 2000; 96 Vollenweider (10.1002/ajmg.b.30197-BIB28) 2001; 56 Fossella (10.1002/ajmg.b.30197-BIB13) 2002; 3 Turecki (10.1002/ajmg.b.30197-BIB27) 1999; 156 Goldberg (10.1002/ajmg.b.30197-BIB14) 2003; 60 Polesskaya (10.1002/ajmg.b.30197-BIB19) 2002; 67 Tellegen (10.1002/ajmg.b.30197-BIB26) 1974; 83 Fan (10.1002/ajmg.b.30197-BIB11) 2003; 100 Syvänen (10.1002/ajmg.b.30197-BIB24) 1997; 7 Aghajanian (10.1002/ajmg.b.30197-BIB2) 1999; 21 Finkel (10.1002/ajmg.b.30197-BIB12) 1997; 72 Goodman (10.1002/ajmg.b.30197-BIB15) 2002; 34 Raz (10.1002/ajmg.b.30197-BIB22) 2002; 59 Crawford (10.1002/ajmg.b.30197-BIB8) 1994; 42 Rainville (10.1002/ajmg.b.30197-BIB21) 2002; 14 Ritz (10.1002/ajmg.b.30197-BIB23) 1995; 41 Tellegen (10.1002/ajmg.b.30197-BIB25) 1982 Comings (10.1002/ajmg.b.30197-BIB7) 2000; 10 Lachman (10.1002/ajmg.b.30197-BIB16) 1996; 6 Lichtenberg (10.1002/ajmg.b.30197-BIB17) 2000; 96 Borg (10.1002/ajmg.b.30197-BIB5) 2003; 160 Williams (10.1002/ajmg.b.30197-BIB30) 1996; 347 Dietrich (10.1002/ajmg.b.30197-BIB9) 2003; 12 Porras (10.1002/ajmg.b.30197-BIB20) 2002; 26 Donnelly (10.1002/ajmg.b.30197-BIB10) 1998; 83 Ando (10.1002/ajmg.b.30197-BIB3) 2002; 70 Abdolmaleky (10.1002/ajmg.b.30197-BIB1) 2004; 67 |
References_xml | – reference: Ritz T, Dahme B. 1995. Die Absorption-Skala: Konzeptuelle Aspekte, psychometrische Kennwerte und Dimensionalität einer deutschsprachigen Adaptation [The Absorption Scale: Conceptual aspects, psychometric properties, and dimensionality of a German adaptation]. Diagnostica 41: 53-61. – reference: Nichols DE. 2004. Hallucinogens. Pharmacol Ther 101: 131-181. – reference: Williams J, Spurlock G, McGuffin P, Mallet J, Nothen MM, Gill M, Aschauer H, Nylander PO, Macciardi F, Owen MJ. 1996. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group. Lancet 347: 1294-1296. – reference: Bondy B, Kuznik J, Baghai T, Schule C, Zwanzger P, Minov C, de Jonge S, Rupprecht R, Meyer H, Engel RR, Eisenmenger W, Ackenheil M. 2000. Lack of association of serotonin-2A receptor gene polymorphism (T102C) with suicidal ideation and suicide. Am J Med Genet 96: 831-835. – reference: Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS, Goldman D, Weinberger DR. 2003. Executive subprocesses in working memory: Relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 60: 889-896. – reference: Cloninger CR, Przybeck TR, Svrakic DM, Wetzel RD. 1994. The temperament and character inventory: A guide to its development and use. St Louis: Washington University Center for Psychobiology of Personality. – reference: Comings DE, Gonzales N, Saucier G, Johnson JP, MacMurray JP. 2000. The DRD4 gene and the spiritual transcendence scale of the character temperament index. Psychiatr Genet 10: 185-189. – reference: Fan J, Fossella J, Sommer T, Wu Y, Posner MI. 2003. Mapping the genetic variation of executive attention onto brain activity. Proc Natl Acad Sci USA 100: 7406-7411. – reference: Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. 1996. Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6: 243-250. – reference: Crawford HJ. 1994. Brain dynamics and hypnosis-attentional and disattentional processes. Int J Clin Exp Hypn 42: 204-232. – reference: Donnelly JP. 1998. A continuum model of personality disorder. Psychol Rep: 83: 387-391. – reference: Finkel D, McGue M. 1997. Sex differences and nonadditivity in heritability of the Multidimensional Personality Questionnaire Scales. J Pers Soc Psychol 72(4): 929-938. – reference: Rainville P, Hofbauer RK, Bushnell MC, Duncan FH, Price DD. 2002. Hypnosis modulates activity in brain structures involved in the regulation of consciousness. J Cogn Neurosci 14: 887-901. – reference: Turecki G, Brière R, Dewar K, Antonetti T, Lesage AD, Séguin M, Chawky N, Vanier C, Alda M, Joober R, Benkelfat C, Rouleau GA. 1999. Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am J Psychiatry 156: 1456-1458. – reference: Vollenweider FX, Geyer MA. 2001. A systems model of altered consciousness: Integrating natural and drug-induced psychosis. Brain Res Bull 56: 495-507. – reference: Polesskaya OO, Sokolov BP. 2002. Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 67: 812-822. – reference: Porras G, Di Matteo V, Fracasso C, Lucas G, De Deurwaerdere P, Caccia S, Esposito E, Spampinato U. 2002. 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 26: 311-324. – reference: Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Baebler A, Vogel H, Hell D. 1998. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 9: 3897-3902. – reference: Aghajanian GK, Marek GJ. 1999. Serotonin and hallucinogens. Neuropsychopharmacology 21: 16S-23S. – reference: Ando J, Ono Y, Yoshimura K, Onoda N, Shinohara M, Kanba S, Asai M. 2002. The genetic structure of Cloninger's seven-factor model of temperament and character in a Japanese sample. J Pers 70: 583-609. – reference: Lichtenberg P, Bachner-Melman R, Gritsenko I, Ebstein RP. 2000. Exploratory association study between catechol-O-methyltransferase (COMT) high/low enzyme activity polymorphism and hypnotizability. Am J Med Genet (Neuropsychiatr Genet) 96: 771-774. – reference: Raz A, Shapiro T. 2002. Hypnosis and neuroscience: A cross talk between clinical and cognitive research. Arch Gen Psychiatry 59: 85-90. – reference: Borg J, Andrée B, Soderstrom H, Farde L. 2003. The serotonin system and spiritual experiences. Am J Psychiatry 160: 1965-1969. – reference: Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT. 2004. Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr Res 67: 53-62. – reference: Tellegen A. 1982. Brief manual for the multidimensional personality questionnaire. Unpublished manuscript. Minneapolis: University of Minnesota. – reference: Tellegen A, Atkinson G. 1974. Openness to absorbing and self-altering experiences ("absorption"), a trait related to hypnotic susceptibility. J Abnorm Psychol 83: 268-277. – reference: Goodman N. 2002. The serotonergic system and mysticism: Could LSD and the nondrug-induced mystical experience share common neural mechanisms? J Psychoactive Drugs 34: 263-272. – reference: Syvänen AC, Tilgmann C, Rinne J, Ulmanen I. 1997. Genetic polymorphism of catechol-O-methyltransferase (COMT): Correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics 7: 65-71. – reference: Dietrich A. 2003. Functional neuroanatomy of altered states of consciousness: The transient hypofrontality hypothesis. Conscious Cogn 12: 231-256. – reference: Fossella J, Sommer T, Fan J, Wu Y, Swanson JM, Pfaff DW, Posner MI. 2002. Assessing the molecular genetics of attention networks. BMC Neuroscience 3: 14. – volume: 101 start-page: 131 year: 2004 end-page: 181 article-title: Hallucinogens publication-title: Pharmacol Ther – volume: 9 start-page: 3897 year: 1998 end-page: 3902 article-title: Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action publication-title: NeuroReport – volume: 14 start-page: 887 year: 2002 end-page: 901 article-title: Hypnosis modulates activity in brain structures involved in the regulation of consciousness publication-title: J Cogn Neurosci – volume: 26 start-page: 311 year: 2002 end-page: 324 article-title: 5‐HT2A and 5‐HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum publication-title: Neuropsychopharmacology – volume: 42 start-page: 204 year: 1994 end-page: 232 article-title: Brain dynamics and hypnosis—attentional and disattentional processes publication-title: Int J Clin Exp Hypn – volume: 100 start-page: 7406 year: 2003 end-page: 7411 article-title: Mapping the genetic variation of executive attention onto brain activity publication-title: Proc Natl Acad Sci USA – volume: 67 start-page: 812 year: 2002 end-page: 822 article-title: Differential expression of the “C” and “T” alleles of the receptor gene in the temporal cortex of normal individuals and schizophrenics publication-title: J Neurosci Res – volume: 56 start-page: 495 year: 2001 end-page: 507 article-title: A systems model of altered consciousness: Integrating natural and drug‐induced psychosis publication-title: Brain Res Bull – volume: 60 start-page: 889 year: 2003 end-page: 896 article-title: Executive subprocesses in working memory: Relationship to catechol‐ ‐methyltransferase Val158Met genotype and schizophrenia publication-title: Arch Gen Psychiatry – volume: 83 start-page: 387 year: 1998 end-page: 391 article-title: A continuum model of personality disorder publication-title: Psychol Rep – year: 1994 – volume: 7 start-page: 65 year: 1997 end-page: 71 article-title: Genetic polymorphism of catechol‐ ‐methyltransferase (COMT): Correlation of genotype with individual variation of S‐COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland publication-title: Pharmacogenetics – volume: 70 start-page: 583 year: 2002 end-page: 609 article-title: The genetic structure of Cloninger's seven‐factor model of temperament and character in a Japanese sample publication-title: J Pers – volume: 67 start-page: 53 year: 2004 end-page: 62 article-title: Meta‐analysis of association between the T102C polymorphism of the receptor gene and schizophrenia publication-title: Schizophr Res – year: 1982 – volume: 347 start-page: 1294 year: 1996 end-page: 1296 article-title: Association between schizophrenia and T102C polymorphism of the 5‐hydroxytryptamine type 2a‐receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group publication-title: Lancet – volume: 21 start-page: 16S year: 1999 end-page: 23S article-title: Serotonin and hallucinogens publication-title: Neuropsychopharmacology – volume: 34 start-page: 263 year: 2002 end-page: 272 article-title: The serotonergic system and mysticism: Could LSD and the nondrug‐induced mystical experience share common neural mechanisms? publication-title: J Psychoactive Drugs – volume: 10 start-page: 185 year: 2000 end-page: 189 article-title: The DRD4 gene and the spiritual transcendence scale of the character temperament index publication-title: Psychiatr Genet – volume: 160 start-page: 1965 year: 2003 end-page: 1969 article-title: The serotonin system and spiritual experiences publication-title: Am J Psychiatry – volume: 83 start-page: 268 year: 1974 end-page: 277 article-title: Openness to absorbing and self‐altering experiences (“absorption”), a trait related to hypnotic susceptibility publication-title: J Abnorm Psychol – volume: 72 start-page: 929 issue: 4 year: 1997 end-page: 938 article-title: Sex differences and nonadditivity in heritability of the Multidimensional Personality Questionnaire Scales publication-title: J Pers Soc Psychol – volume: 6 start-page: 243 year: 1996 end-page: 250 article-title: Human catechol‐ ‐methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders publication-title: Pharmacogenetics – volume: 156 start-page: 1456 year: 1999 end-page: 1458 article-title: Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide publication-title: Am J Psychiatry – volume: 59 start-page: 85 year: 2002 end-page: 90 article-title: Hypnosis and neuroscience: A cross talk between clinical and cognitive research publication-title: Arch Gen Psychiatry – volume: 96 start-page: 831 year: 2000 end-page: 835 article-title: Lack of association of serotonin‐2A receptor gene polymorphism ( ) with suicidal ideation and suicide publication-title: Am J Med Genet – volume: 41 start-page: 53 year: 1995 end-page: 61 article-title: Die Absorption‐Skala: Konzeptuelle Aspekte, psychometrische Kennwerte und Dimensionalität einer deutschsprachigen Adaptation [The Absorption Scale: Conceptual aspects, psychometric properties, and dimensionality of a German adaptation] publication-title: Diagnostica – volume: 3 start-page: 14 year: 2002 article-title: Assessing the molecular genetics of attention networks publication-title: BMC Neuroscience – volume: 96 start-page: 771 year: 2000 end-page: 774 article-title: Exploratory association study between catechol‐ ‐methyltransferase (COMT) high/low enzyme activity polymorphism and hypnotizability publication-title: Am J Med Genet (Neuropsychiatr Genet) – volume: 12 start-page: 231 year: 2003 end-page: 256 article-title: Functional neuroanatomy of altered states of consciousness: The transient hypofrontality hypothesis publication-title: Conscious Cogn – volume: 10 start-page: 185 year: 2000 ident: 10.1002/ajmg.b.30197-BIB7 publication-title: Psychiatr Genet doi: 10.1097/00041444-200010040-00006 – volume: 56 start-page: 495 year: 2001 ident: 10.1002/ajmg.b.30197-BIB28 publication-title: Brain Res Bull doi: 10.1016/S0361-9230(01)00646-3 – volume: 72 start-page: 929 year: 1997 ident: 10.1002/ajmg.b.30197-BIB12 publication-title: J Pers Soc Psychol doi: 10.1037/0022-3514.72.4.929 – volume: 26 start-page: 311 year: 2002 ident: 10.1002/ajmg.b.30197-BIB20 publication-title: Neuropsychopharmacology doi: 10.1016/S0893-133X(01)00333-5 – volume: 59 start-page: 85 year: 2002 ident: 10.1002/ajmg.b.30197-BIB22 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.59.1.85 – volume: 60 start-page: 889 year: 2003 ident: 10.1002/ajmg.b.30197-BIB14 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.60.9.889 – volume: 100 start-page: 7406 year: 2003 ident: 10.1002/ajmg.b.30197-BIB11 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0732088100 – volume-title: The temperament and character inventory: A guide to its development and use year: 1994 ident: 10.1002/ajmg.b.30197-BIB6 – volume: 9 start-page: 3897 year: 1998 ident: 10.1002/ajmg.b.30197-BIB29 publication-title: NeuroReport doi: 10.1097/00001756-199812010-00024 – volume: 101 start-page: 131 year: 2004 ident: 10.1002/ajmg.b.30197-BIB18 publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2003.11.002 – volume: 96 start-page: 831 year: 2000 ident: 10.1002/ajmg.b.30197-BIB4 publication-title: Am J Med Genet doi: 10.1002/1096-8628(20001204)96:6<831::AID-AJMG27>3.0.CO;2-K – volume: 347 start-page: 1294 year: 1996 ident: 10.1002/ajmg.b.30197-BIB30 publication-title: Lancet doi: 10.1016/S0140-6736(96)90939-3 – volume: 67 start-page: 812 year: 2002 ident: 10.1002/ajmg.b.30197-BIB19 publication-title: J Neurosci Res doi: 10.1002/jnr.10173 – volume: 3 start-page: 14 year: 2002 ident: 10.1002/ajmg.b.30197-BIB13 publication-title: BMC Neuroscience doi: 10.1186/1471-2202-3-14 – volume: 156 start-page: 1456 year: 1999 ident: 10.1002/ajmg.b.30197-BIB27 publication-title: Am J Psychiatry doi: 10.1176/ajp.156.9.1456 – volume: 70 start-page: 583 year: 2002 ident: 10.1002/ajmg.b.30197-BIB3 publication-title: J Pers doi: 10.1111/1467-6494.05018 – volume-title: Brief manual for the multidimensional personality questionnaire. Unpublished manuscript year: 1982 ident: 10.1002/ajmg.b.30197-BIB25 – volume: 14 start-page: 887 year: 2002 ident: 10.1002/ajmg.b.30197-BIB21 publication-title: J Cogn Neurosci doi: 10.1162/089892902760191117 – volume: 83 start-page: 268 year: 1974 ident: 10.1002/ajmg.b.30197-BIB26 publication-title: J Abnorm Psychol doi: 10.1037/h0036681 – volume: 96 start-page: 771 year: 2000 ident: 10.1002/ajmg.b.30197-BIB17 publication-title: Am J Med Genet (Neuropsychiatr Genet) doi: 10.1002/1096-8628(20001204)96:6<771::AID-AJMG14>3.0.CO;2-T – volume: 12 start-page: 231 year: 2003 ident: 10.1002/ajmg.b.30197-BIB9 publication-title: Conscious Cogn doi: 10.1016/S1053-8100(02)00046-6 – volume: 6 start-page: 243 year: 1996 ident: 10.1002/ajmg.b.30197-BIB16 publication-title: Pharmacogenetics doi: 10.1097/00008571-199606000-00007 – volume: 42 start-page: 204 year: 1994 ident: 10.1002/ajmg.b.30197-BIB8 publication-title: Int J Clin Exp Hypn doi: 10.1080/00207149408409352 – volume: 67 start-page: 53 year: 2004 ident: 10.1002/ajmg.b.30197-BIB1 publication-title: Schizophr Res doi: 10.1016/S0920-9964(03)00183-X – volume: 160 start-page: 1965 year: 2003 ident: 10.1002/ajmg.b.30197-BIB5 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.160.11.1965 – volume: 41 start-page: 53 year: 1995 ident: 10.1002/ajmg.b.30197-BIB23 publication-title: Diagnostica – volume: 83 start-page: 387 year: 1998 ident: 10.1002/ajmg.b.30197-BIB10 publication-title: Psychol Rep doi: 10.2466/PR0.83.6.387-391 – volume: 7 start-page: 65 year: 1997 ident: 10.1002/ajmg.b.30197-BIB24 publication-title: Pharmacogenetics doi: 10.1097/00008571-199702000-00009 – volume: 34 start-page: 263 year: 2002 ident: 10.1002/ajmg.b.30197-BIB15 publication-title: J Psychoactive Drugs doi: 10.1080/02791072.2002.10399962 – volume: 21 start-page: 16s year: 1999 ident: 10.1002/ajmg.b.30197-BIB2 publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1395318 |
SSID | ssj0030577 |
Score | 2.0607357 |
Snippet | Absorption represents a disposition to experience altered states of consciousness characterized by intensively focused attention. It is correlated with... |
SourceID | proquest pubmed crossref wiley istex |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 29 |
SubjectTerms | absorption trait Adult Alleles Attention - physiology Catechol O-Methyltransferase - genetics dopamine Epistasis, Genetic Female Gene Frequency Genotype Hallucinations - genetics Hallucinations - physiopathology Humans Male molecular genetics Polymorphism, Genetic Receptor, Serotonin, 5-HT2A - genetics Schizophrenia - genetics Schizophrenia - physiopathology serotonin T102C |
Title | Evidence for a common biological basis of the absorption trait, hallucinogen effects, and positive symptoms: Epistasis between 5-HT2a and COMT polymorphisms |
URI | https://api.istex.fr/ark:/67375/WNG-5SKXDPGP-N/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fajmg.b.30197 https://www.ncbi.nlm.nih.gov/pubmed/15965969 https://www.proquest.com/docview/68076101 |
Volume | 137B |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbhMxFLVQEYgNj_IKTy-ADZnU8_B4zK7qI1FRQgWpyM6yZzxQ2sxEmQkirPgEvoCP40u41zNJKQIk2Hnht4_tY_v6XEKeJBy9FJnE00YyL4ItD0Ii8ALNWRrHUvMQPycPR_HgKDqY8El74YZ_YRp9iPWFG84Mt17jBNem2joTDdUfpu96pgcAlfiZ3A9jlM7ffb1WjwIkO8eLKDLmRUnkt3bvkHzr58TndqSL2Lmffkc3z7NXt_3sXyNqVfHG6uSkt6hNL_38i6bj_7fsOrnaMlO63UDpBrlgi01yqfFVudwkl4ftK_xN8m3lipQC46WaQv4AZtroOeGgU9gbjyta5hToJYViy7lbmSg6pKi7FB24LCCvEtBLW4uSLtVFRhsbso-WVsvprC6n1Qu6N0OKi_m1NmWUf__ydTAOtEux82o4hmSnyykU8v64mla3yNH-3nhn4LV-HrwUTq_Ck4kvYhtkvs0S309ToRMpWC4Ys8KEGcuMSP1EZiEH8sFiGRiWBnksTM6SnOk0vE02irKwdwnNo1CwzDKrdRJJa43kQHHgVJYH2kqWdcjz1VirtBVBx6afqka-OVDY-coo1_kd8nQde9aIf_wh3jMHm3UkPT9BgznB1dtRX_E3Lye7h_1DNeqQxytcKZjG-DajC1suKhUneKHE_A6508DtrECOmo-x7JCuA81fa6K2D4Z9F7r3b9HvkytOlBaNYfgDslHPF_Yh0K3aPHKT6gcVdSe- |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LctMwFNVAOzw2PAqU8KoWwIY4lR3Lsth1-khom9CBdJqdkGy5lDZxJk4YwopP4Av4OL6Ee2UnpQwww7DTQm8dSUfS1bmEPI05eikysaeNZF4IWx6EROAFmrMkiqTmTfyc3OlG7cNwt8_7lZ9T_AtT6kMsLtxwZrj1Gic4Xkivn6uG6g-D44ZpAEKluEyWQ-AaePraerPQjwIsO9eLKDPmhXHoV5bvkH7959QX9qRl7N5PvyOcF_mr24B2bpJ386qXdienjenENJLPv6g6_kfbbpEbFTmlGyWabpNLdrhCrpTuKmcr5Gqneoi_Q77NvZFSIL1UUygA8ExLSSccdwrb40lB84wCw6TaFPnYLU4UfVJM6hR9uEwhrxwATCujkjrVw5SWZmQfLS1mg9EkHxQv6fYIWS7mV5mVUf79y9d2L9AuxebrTg-Snc0GUMj7k2JQ3CWHO9u9zbZXuXrwEjjACk_GvohskPo2jX0_SYSOpWCZYMwK00xZakTixzJtcuAfLJKBYUmQRcJkLM6YTpr3yNIwH9r7hGZhU7DUMqt1HEprjeTAcuBglgXaSpbWyIv5YKuk0kHHpp-pUsE5UNj5yijX-TXybBF7VOp__CHec4ebRSQ9PkWbOcHVUbel-Nu9_tZB60B1a2RtDiwFMxmfZ_TQ5tNCRTHeKTG_RlZLvJ0XyFH2MZI1Uneo-WtN1MZup-VCD_4t-hq51u519tX-q-7eQ3LdadSibQx_RJYm46l9DOxrYp64GfYDeVMr3Q |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LctMwFNVAO3TY8Cgv86oWwIY4lR-yLHadtkloSchAOs1OI9kylDZ2JnYYwopP4Av4OL6EK9lJKQPMwE4LvXUkHUlX5yL0JKbGS5GKXak4cUPY8iDEfNeXlCRRxCUNzOfk_iDqHYUHYzpuLtzMX5haH2J14WZmhl2vzQSfptn2uWio_DB511ZtAChnl9F6GAGZMKTozUo-CqBsPS8alTE3jEOvMXyH9Ns_p76wJa2b3v30O755kb7a_adzHYllzWuzk9P2vFLt5PMvoo7_37Qb6FpDTfFOjaWb6JLON9GV2lnlYhNt9Jtn-Fvo29IXKQbKiyWG_AHNuBZ0MqOOYXM8KXGRYeCXWKqymNmlCRuPFFULGw8uc8irAPjixqSkhWWe4tqI7KPG5WIyrYpJ-QLvTw3HNfk1RmWYfv_ytTfypU2x-7o_gmRniwkU8v6knJS30VFnf7TbcxtHD24Cx1fm8thjkfZTT6ex5yUJkzFnJGOEaKaClKSKJV7M04AC-yAR9xVJ_CxiKiNxRmQS3EFreZHrewhnYcBIqomWMg651opT4DhwLMt8qTlJHfR8OdYiaVTQTdPPRK3f7AvT-UIJ2_kOerqKPa3VP_4Q75mFzSqSnJ0aizlGxfGgK-jbw_HesDsUAwdtLXElYB6bxxmZ62Jeiig2N0rEc9DdGm7nBVIj-hhxB7UsaP5aE7Fz0O_a0P1_i76FNoZ7HfHq5eDwAbpqBWqNYQx9iNaq2Vw_AupVqcd2fv0A3VoqjA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evidence+for+a+common+biological+basis+of+the+Absorption+trait%2C+hallucinogen+effects%2C+and+positive+symptoms%3A+epistasis+between+5-HT2a+and+COMT+polymorphisms&rft.jtitle=American+journal+of+medical+genetics.+Part+B%2C+Neuropsychiatric+genetics&rft.au=Ott%2C+Ulrich&rft.au=Reuter%2C+Martin&rft.au=Hennig%2C+Juergen&rft.au=Vaitl%2C+Dieter&rft.date=2005-08-05&rft.issn=1552-4841&rft.volume=137B&rft.issue=1&rft.spage=29&rft_id=info:doi/10.1002%2Fajmg.b.30197&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1552-4841&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1552-4841&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1552-4841&client=summon |